[go: up one dir, main page]

MX2021000595A - Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin- 6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida. - Google Patents

Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin- 6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida.

Info

Publication number
MX2021000595A
MX2021000595A MX2021000595A MX2021000595A MX2021000595A MX 2021000595 A MX2021000595 A MX 2021000595A MX 2021000595 A MX2021000595 A MX 2021000595A MX 2021000595 A MX2021000595 A MX 2021000595A MX 2021000595 A MX2021000595 A MX 2021000595A
Authority
MX
Mexico
Prior art keywords
triazin
quinolin
imidazo
ylmethyl
fluoro
Prior art date
Application number
MX2021000595A
Other languages
English (en)
Inventor
Elisabete Goncalves
Christin Tauchmann
Shau-Fong Yen
Sudha Vippagunta
Zhixin Zong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021000595(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021000595A publication Critical patent/MX2021000595A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con tabletas que comprenden 2-fluoro-N-metil-4-[7- (quinolin-6-ilmetil)imidazo[1,2-b] [1,2,4] triazin-2-il]benzamida, procesos para la producción de los mismos, y usos en el tratamiento de ciertos tipos de cáncer.
MX2021000595A 2014-07-25 2017-01-25 Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin- 6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida. MX2021000595A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028865P 2014-07-25 2014-07-25

Publications (1)

Publication Number Publication Date
MX2021000595A true MX2021000595A (es) 2021-04-13

Family

ID=53762251

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017001177A MX379279B (es) 2014-07-25 2015-07-22 Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil) imidazo[1,2,b] [1,2,4]triazin-2-il]benzamida.
MX2021000595A MX2021000595A (es) 2014-07-25 2017-01-25 Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin- 6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017001177A MX379279B (es) 2014-07-25 2015-07-22 Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil) imidazo[1,2,b] [1,2,4]triazin-2-il]benzamida.

Country Status (31)

Country Link
US (4) US10085993B2 (es)
EP (2) EP3848376A1 (es)
JP (3) JP6770946B2 (es)
KR (2) KR20230136693A (es)
CN (2) CN115364061A (es)
AR (1) AR101286A1 (es)
AU (4) AU2015293539A1 (es)
CA (1) CA2954840A1 (es)
CL (1) CL2017000180A1 (es)
CO (1) CO2017000586A2 (es)
DK (1) DK3172209T3 (es)
EA (2) EA039220B1 (es)
EC (1) ECSP17011672A (es)
ES (1) ES2857523T3 (es)
FR (1) FR22C1058I2 (es)
GT (1) GT201700007A (es)
HU (2) HUE053346T2 (es)
IL (1) IL250166B (es)
JO (1) JO3618B1 (es)
MX (2) MX379279B (es)
MY (1) MY187276A (es)
NL (1) NL301208I2 (es)
NO (1) NO2022058I1 (es)
PE (1) PE20170523A1 (es)
PH (1) PH12017500121A1 (es)
PL (1) PL3172209T3 (es)
PT (1) PT3172209T (es)
SG (2) SG10201900648SA (es)
SI (1) SI3172209T1 (es)
TW (2) TW202200148A (es)
WO (1) WO2016012963A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2660354C2 (ru) 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
PE20170523A1 (es) 2014-07-25 2017-05-17 Novartis Ag Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida
MX2019001579A (es) 2016-08-10 2019-06-20 Hoffmann La Roche Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
US11407735B2 (en) 2019-05-16 2022-08-09 Novartis Ag Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
IL292455A (en) * 2019-10-24 2022-06-01 Hanmi Pharm Ind Co Ltd A pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
CN114853762A (zh) * 2021-02-03 2022-08-05 四川科伦药物研究院有限公司 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
CN118251220A (zh) * 2022-01-19 2024-06-25 江苏奥赛康药业有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN120112284A (zh) * 2022-08-19 2025-06-06 米拉蒂治疗股份有限公司 阿达格拉西布固体药物组合物
TW202504611A (zh) 2023-03-30 2025-02-01 美商銳新醫藥公司 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762778B1 (en) 1999-06-10 2004-07-13 Dassault Systemes Three dimensional graphical manipulator
CA2465565A1 (en) 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20070042034A1 (en) * 2005-07-22 2007-02-22 Myriad Genetics, Incorporated High drug load formulations and dosage forms
BRPI0615898B8 (pt) 2005-09-12 2021-05-25 Actelion Pharmaceuticals Ltd composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
CN101641093B (zh) 2006-11-22 2013-05-29 因塞特公司 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶
WO2009143211A2 (en) * 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
ES2757882T5 (es) * 2009-11-09 2023-05-10 Wyeth Llc Formulaciones de comprimidos de maleato de neratinib
DK2538925T3 (en) 2010-02-25 2016-03-14 Bristol Myers Squibb Co Apixabanformuleringer
MY161078A (en) * 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
US20120009259A1 (en) 2010-07-06 2012-01-12 Urbain Alfons Clementina Delaet Formulation for co-therapy treatment of diabetes
US20150216870A1 (en) 2012-08-16 2015-08-06 Novartis Ag Combination of PI3K Inhibitor and C-Met Inhibitor
PE20170523A1 (es) 2014-07-25 2017-05-17 Novartis Ag Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida

Also Published As

Publication number Publication date
TW201613595A (en) 2016-04-16
WO2016012963A1 (en) 2016-01-28
EP3172209A1 (en) 2017-05-31
JP2017521469A (ja) 2017-08-03
TWI724993B (zh) 2021-04-21
US10085993B2 (en) 2018-10-02
CL2017000180A1 (es) 2017-09-15
MY187276A (en) 2021-09-17
AU2020200912A1 (en) 2020-02-27
US20210113569A1 (en) 2021-04-22
CN115364061A (zh) 2022-11-22
HUE053346T2 (hu) 2021-06-28
TW202200148A (zh) 2022-01-01
EA039220B1 (ru) 2021-12-20
ES2857523T3 (es) 2021-09-29
JP2022046659A (ja) 2022-03-23
AU2015293539A1 (en) 2017-02-02
PL3172209T3 (pl) 2021-06-14
PT3172209T (pt) 2021-02-11
EA202191301A1 (ru) 2021-11-30
SI3172209T1 (sl) 2021-03-31
PE20170523A1 (es) 2017-05-17
CN106714784A (zh) 2017-05-24
CA2954840A1 (en) 2016-01-28
JP7002587B2 (ja) 2022-01-20
JP2020114852A (ja) 2020-07-30
KR20170039211A (ko) 2017-04-10
EA201790259A1 (ru) 2017-06-30
US20190015418A1 (en) 2019-01-17
JO3618B1 (ar) 2020-08-27
MX379279B (es) 2025-03-11
NL301208I2 (nl) 2025-03-20
CO2017000586A2 (es) 2017-06-20
KR20230136693A (ko) 2023-09-26
US10596178B2 (en) 2020-03-24
ECSP17011672A (es) 2018-03-31
KR102581121B1 (ko) 2023-09-21
AU2020200912B2 (en) 2021-01-28
SG10201900648SA (en) 2019-02-27
NO2022058I1 (no) 2022-12-16
AU2021202500A1 (en) 2021-05-20
AR101286A1 (es) 2016-12-07
AU2018207947A1 (en) 2018-08-09
IL250166B (en) 2021-01-31
HUS2200054I1 (hu) 2023-01-28
US12208101B2 (en) 2025-01-28
JP6770946B2 (ja) 2020-10-21
US20170231997A1 (en) 2017-08-17
FR22C1058I1 (fr) 2023-01-06
GT201700007A (es) 2018-12-18
SG11201700147SA (en) 2017-02-27
EP3172209B1 (en) 2020-12-02
FR22C1058I2 (fr) 2023-11-17
NZ728089A (en) 2024-01-26
EP3848376A1 (en) 2021-07-14
MX2017001177A (es) 2017-05-01
DK3172209T3 (da) 2021-02-22
PH12017500121A1 (en) 2017-05-29
IL250166A0 (en) 2017-03-30
BR112017000953A2 (pt) 2017-11-14
US20220249498A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
MX2021000595A (es) Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin- 6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida.
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
WO2016134335A3 (en) Pvrig polypeptides and methods of treatment
JO3512B1 (ar) مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
TN2016000107A1 (en) Substituted phenylalanine derivatives
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
PH12015500322B1 (en) Tris(hetero)arylpyrazoles and use thereof
MX375551B (es) Nuevas imidazo[1,2-a]quinoxalinas y derivados de las mismas para el tratamiento contra cancer.
CA166429S (en) Baby monitor
TH1701000365A (th) สูตรตำรับยาเม็ดแบนของ2-ฟลูออโร-N-เมธิล-4-[7-(ควิโนลิน-6-อิลเมธิล)อิมิดาโซ[1,2-b][1,2,4]ไตรอะซิน-2-อิล]เบนซาไมด์
CA166428S (en) Baby monitor